Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab as Primary Treatment for Extensive Chronic Graft Versus Host Disease
NCT01161628Phase 2Completed
- Sponsor
- Northside Hospital
- Start
- Apr 2011
- Primary completion
- Jan 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in chronic graft-versus-host disease (cGVHD), sponsored by Northside Hospital. Primary endpoints: Rate of Complete Response of cGVHD to Treatment at 2 years, Rate of Overall Response of cGVHD to Treatment at 2 years and 1 more. Started Apr 2011; status: completed.
02
Drugs
rituximab
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT01161628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01161628.